Based on these results, the most recent American guideline recommends the combination of an OAC and a P2Y12 inhibitor as DAT in patients with AF who undergo PCI with stenting for ACS [66], although the European Society of Cardiology states that one month of TAT can be considered based on the patient’s bleeding and ischemic risks [8]. The gene discussed is P2RY12; the disease is atrial fibrillation.